Cargando…

Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review

Human papillomavirus (HPV) is an important cause of anogenital and oropharyngeal cancers, anogenital warts, and recurrent respiratory papillomatosis. Beginning in 2019, US guidelines recommended shared clinical decision-making (SCDM) for HPV vaccination among midadults (27–45 years). We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Laura M, Lewnard, Joseph A, Niccolai, Linda M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887268/
https://www.ncbi.nlm.nih.gov/pubmed/36726535
http://dx.doi.org/10.1093/ofid/ofad004
_version_ 1784880304152903680
author King, Laura M
Lewnard, Joseph A
Niccolai, Linda M
author_facet King, Laura M
Lewnard, Joseph A
Niccolai, Linda M
author_sort King, Laura M
collection PubMed
description Human papillomavirus (HPV) is an important cause of anogenital and oropharyngeal cancers, anogenital warts, and recurrent respiratory papillomatosis. Beginning in 2019, US guidelines recommended shared clinical decision-making (SCDM) for HPV vaccination among midadults (27–45 years). We conducted a narrative review of existing literature on HPV vaccination in midadults. The available evidence demonstrates that HPV vaccination in midadults is safe, efficacious, and likely to benefit both HPV-naïve midadults and those with previous infections. However, gaps in knowledge related to HPV vaccination have been identified among clinicians and midadult patients. Universal midadult HPV vaccination in the United States could avert 20 934–37 856 cancer cases over 100 years, costing $141 000–$1 471 000 per quality-adjusted life-year gained. Wide variation in these estimates reflects uncertainties in sexual behavior, HPV natural history, and naturally acquired immunity. Greater awareness among clinicians and midadult patients and broad implementation of SCDM may accelerate progress toward eliminating HPV-associated cancers and other diseases.
format Online
Article
Text
id pubmed-9887268
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98872682023-01-31 Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review King, Laura M Lewnard, Joseph A Niccolai, Linda M Open Forum Infect Dis Review Article Human papillomavirus (HPV) is an important cause of anogenital and oropharyngeal cancers, anogenital warts, and recurrent respiratory papillomatosis. Beginning in 2019, US guidelines recommended shared clinical decision-making (SCDM) for HPV vaccination among midadults (27–45 years). We conducted a narrative review of existing literature on HPV vaccination in midadults. The available evidence demonstrates that HPV vaccination in midadults is safe, efficacious, and likely to benefit both HPV-naïve midadults and those with previous infections. However, gaps in knowledge related to HPV vaccination have been identified among clinicians and midadult patients. Universal midadult HPV vaccination in the United States could avert 20 934–37 856 cancer cases over 100 years, costing $141 000–$1 471 000 per quality-adjusted life-year gained. Wide variation in these estimates reflects uncertainties in sexual behavior, HPV natural history, and naturally acquired immunity. Greater awareness among clinicians and midadult patients and broad implementation of SCDM may accelerate progress toward eliminating HPV-associated cancers and other diseases. Oxford University Press 2023-01-11 /pmc/articles/PMC9887268/ /pubmed/36726535 http://dx.doi.org/10.1093/ofid/ofad004 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Review Article
King, Laura M
Lewnard, Joseph A
Niccolai, Linda M
Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review
title Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review
title_full Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review
title_fullStr Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review
title_full_unstemmed Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review
title_short Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review
title_sort clinical and public health considerations for hpv vaccination in midadulthood: a narrative review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887268/
https://www.ncbi.nlm.nih.gov/pubmed/36726535
http://dx.doi.org/10.1093/ofid/ofad004
work_keys_str_mv AT kinglauram clinicalandpublichealthconsiderationsforhpvvaccinationinmidadulthoodanarrativereview
AT lewnardjosepha clinicalandpublichealthconsiderationsforhpvvaccinationinmidadulthoodanarrativereview
AT niccolailindam clinicalandpublichealthconsiderationsforhpvvaccinationinmidadulthoodanarrativereview